• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Establishment Labs Appoints Peter Caldini as Chief Executive Officer

    5/7/25 4:00:00 PM ET
    $ESTA
    Industrial Specialties
    Health Care
    Get the next $ESTA alert in real time by email

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role.

    "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision and a mission that is very clear, and execution is paramount to ensure that we accomplish all our goals, including turning EBITDA positive in 2025 and cash flow positive in 2026. Our Founder, Juan José Chacón-Quirós continues as a board member and an integral part of the team, from supporting our continued R&D efforts, to ensuring the adoption of our products and technologies by the plastic surgery community. He will advocate around the world for Establishment Labs and its contributions to women's health."

    "It is an honor to be leading Establishment Labs," added Peter Caldini. "Our company has transformed breast aesthetics and reconstruction globally though innovation and science, and it is in a unique position to do so again as we launch in the United States. We are building an incredibly strong moat in a multibillion-dollar market. Our product suite is one of the most differentiated in medtech, and we are working aggressively to take and expand the market. Most exciting to me is what is in front of us: the chance to marry innovation and best-in-class products with operational excellence so that we can deliver to all our stakeholders, including women, plastic surgeons, and investors."

    Fillipo "Peter" Caldini joined Establishment Labs as President in 2024. Previously, he served as the Chief Executive Officer and Director of Acreage Holdings, Inc. from 2020 to 2023 and of Bespoke Capital Acquisition Corp from 2019 to 2020. From 2015 to 2019, Mr. Caldini worked at Pfizer Consumer Healthcare where he was the Regional President for North America and prior to that role, Regional President of EMEA. He worked at Bayer Consumer Healthcare from 2009 to 2014 where he held several roles of increasing responsibility, including Head of Emerging Markets, GM China, and Head of the Nutritionals Strategic Business Unit. Mr. Caldini received his undergraduate degree from Boston University, his MBA from Northeastern University, and a Master's in International Economics and Management from SDA Bocconi.

    About Establishment Labs

    Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zenº™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507043815/en/

    Investor/Media Contact:

    Raj Denhoy

    415 828-1044

    [email protected]

    Get the next $ESTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ESTA

    DatePrice TargetRatingAnalyst
    4/14/2025Hold
    Needham
    5/22/2024$60.00Buy → Neutral
    Citigroup
    8/31/2023$75.00Overweight
    JP Morgan
    6/29/2023$79.00Buy
    Citigroup
    10/14/2022$90.00Overweight
    Stephens
    10/13/2022$70.00Buy
    Mizuho
    8/24/2022$107.00Buy
    B. Riley Securities
    11/10/2021$88.00 → $90.00Overweight
    Stephens & Co.
    More analyst ratings

    $ESTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel and CCO Mansbach Samuel Ross was granted 7,952 shares, increasing direct ownership by 109% to 15,238 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      4/4/25 4:50:37 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Chief Financial Officer Denhoy Raj was granted 11,200 shares, increasing direct ownership by 92% to 23,348 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      4/4/25 4:49:52 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Int Chief Executive Officer Caldini Filippo was granted 17,231 shares, increasing direct ownership by 207% to 25,539 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      4/4/25 4:48:39 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Establishment Labs Holdings Inc.

      DEFA14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/7/25 4:05:26 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/7/25 4:04:12 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/7/25 4:01:39 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lewin Nicholas Sheridan bought $54,073 worth of shares (2,000 units at $27.04), increasing direct ownership by 0.19% to 1,064,888 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      12/15/23 7:59:37 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Lewin Nicholas Sheridan bought $110,000 worth of shares (5,000 units at $22.00) (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      11/21/23 8:00:55 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Denhoy Raj bought $49,972 worth of shares (2,250 units at $22.21), increasing direct ownership by 38% to 8,112 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      11/20/23 8:00:42 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Establishment Labs Appoints Peter Caldini as Chief Executive Officer

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Announces CEO Transition

      Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active

      1/13/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year. "Jeff is the ideal person to introduce Motiva to the United States," said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs. "Just as we have changed the standard for breast augmentat

      5/1/24 8:30:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Financials

    Live finance-specific insights

    See more

    $ESTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ESTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ESTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Establishment Labs Reports First Quarter 2025 Financial Results

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. 2025 revenue guidance maintained at $205 million to $210 million, year over year growth of 23%–26%. First quarter gross margin of 67.2% compared to 65.6% in the year-ago period. First quarter loss from operations was $16.9 million compared to a loss of $8.8 million in the ye

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs to Announce First Quarter 2025 Financial Results on May 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2025, after the market closes on Wednesday, May 7, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750827. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establis

      4/24/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2024 and reaffirmed 2025 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $44.5 million, consistent with preannouncement on January 13. Motiva Implants approved and launched in U.S.; Motiva U.S. revenue in the fourth quarter of $3.3 million. Fourth quarter net loss from operations of $18.7 million, a 15% reduction compared to a net loss of $22.1 million in the year-ago period. F

      2/26/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Reports First Quarter 2025 Financial Results

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. 2025 revenue guidance maintained at $205 million to $210 million, year over year growth of 23%–26%. First quarter gross margin of 67.2% compared to 65.6% in the year-ago period. First quarter loss from operations was $16.9 million compared to a loss of $8.8 million in the ye

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Appoints Peter Caldini as Chief Executive Officer

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs to Announce First Quarter 2025 Financial Results on May 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2025, after the market closes on Wednesday, May 7, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750827. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establis

      4/24/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Establishment Labs Holdings Inc.

      SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      11/12/24 12:54:20 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Establishment Labs Holdings Inc.

      SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      11/12/24 9:03:38 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

      SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      2/14/24 4:51:40 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Needham initiated coverage on Establishment Labs

      Needham initiated coverage of Establishment Labs with a rating of Hold

      4/14/25 7:48:56 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs downgraded by Citigroup with a new price target

      Citigroup downgraded Establishment Labs from Buy to Neutral and set a new price target of $60.00

      5/22/24 7:26:41 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • JP Morgan initiated coverage on Establishment Labs with a new price target

      JP Morgan initiated coverage of Establishment Labs with a rating of Overweight and set a new price target of $75.00

      8/31/23 7:13:36 AM ET
      $ESTA
      Industrial Specialties
      Health Care